Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma

01-jun-2008 | Revista: Clinical and Translational Oncology

Marta Santisteban (1), José Luis Pérez-Gracia (1), Jaime Ceballos (1), Isabel Vivas (2) and Jesús García-Foncillas (1)
(1) Medical Oncology Department, Clínica Universitaria de Navarra, Avda. Pío XII, 36, ES-31008 Pamplona, Spain
(2) Radiology Department, Clínica Universitaria de Navarra, Pamplona, Spain


We report a case of hormone-refractory prostate cancer (HRPC) treated with oxaliplatin plus gemcitabine in a third-line schedule after liver progression, with an excellent clinical, biochemical and radiological response and with an acceptable tolerance. Prior chemotherapy regimens included docetaxel plus estramustine and oral etoposide.

To our knowledge, this is the first report that shows this approach in an HRPC patient.

CITA DEL ARTICULO  Clin Transl Oncol. 2008 Jun;10(6):372-4.